It’s quickly become evident that GLP-1 drugs for diabetes, weight loss, and more are the new wonder drugs—if only people ...

Britons paying privately for obesity drugs are increasingly choosing Eli Lilly's Mounjaro over Novo Nordisk's Wegovy, online ...

Over 18 months, people taking Zepbound lost more weight on average than those on Wegovy, according to the first head-to-head ...

Weight loss drugs such as Ozempic and Wegovy are increasingly popular among adults, who have flocked to the new medication as ...

Zepbound, a drug with the main active ingredient tirzepatide, was found to be more helpful in helping people lose weight than ...

Over half of American adults are eligible for semaglutide, but insurance and other barriers make it hard for people to access ...

W ith more people taking the weight-loss drugs Wegovy and Zepbound, one question inevitably arises: which one is more ...

Eli Lilly said on Wednesday patients taking its obesity drug Zepbound lost 47% more weight than those who were given Novo ...

Eli Lilly said patients taking its obesity drug Zepbound lost 47% more weight than those who were given Novo Nordisk's Wegovy ...

Novo Nordisk's team in India has been pushing the Danish drugmaker's global leadership for an earlier launch of its popular ...

Adults taking Zepbound lost 47% more weight on average than those taking Wegovy, according to clinical trial data from ...

Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has outperformed its main competitor, Wegovy, in a clinical ...